DOI QR코드

DOI QR Code

SULT1A1 Arg213His Polymorphism and Lung Cancer Risk: a Meta-analysis

  • Liao, Shao-Guang (Department of Oncology, Changhai Hospital, Second Military Medical University) ;
  • Liu, Lu (Department of Oncology, Changhai Hospital, Second Military Medical University) ;
  • Zhang, Ying-Yi (Department of Oncology, Changhai Hospital, Second Military Medical University) ;
  • Wang, Ying (Department of Oncology, Changhai Hospital, Second Military Medical University) ;
  • Wang, Ya-Jie (Department of Oncology, Changhai Hospital, Second Military Medical University)
  • Published : 2012.02.29

Abstract

Background: The SULT1A1 Arg213His polymorphism is reported to be associated with lung cancer risk. However, this relationship remains controversial. For better understanding a meta-analysis was therefore performed. Methods: An extensive search was performed to identify all case-control studies investigating association between SULT1A1 Arg213His polymorphism and lung cancer risk. The strength was assessed by odds ratio (OR) with the corresponding 95% confidence interval (95%CI). Results: A total of five publications covering 1,669 cases and 1,890 controls were included in this meta-analysis. No significant association between SULT1A1 Arg213His polymorphism and lung cancer risk was observed in overall comparisons in all genetic models (dominant model: OR=1.33, 95%CI=1.00-1.76, P=0.05; additive model: OR=1.30, 95%CI=0.93-1.81, P=0.12; recessive model: OR=1.21, 95%CI=0.89-1.66, P=0.23). However, on subgroup analysis, an elevated risk in mixed populations with variant His allele was revealed in the dominant model (OR=1.66, 95% CI=1.06-2.62, P=0.03). Furthermore, the SULT1A1 Arg213His polymorphism was associated with an increased risk of lung cancer in both females and males in the dominant model (females: OR=1.72, 95%CI=1.29-2.27, P=0.00; males: OR=1.46, 95%CI=1.19-1.78, P=0.00). No significant association between this polymorphism and different smoking status (smokers and non-smokers) and the other ethnicities (Asians and Caucasians) was shown. Conclusions: The results of this meta-analysis indicate that the SULT1A1 Arg213His polymorphism is not associated with lung cancer risk in Asians and Caucasians, but possible elevation for genotype (GA/AA) in mixed populations and males and females needs further investigation.

Keywords

SULT1A1;lung cancer;genetic polymorphisms;meta-analysis

References

  1. Arlt VM, Glatt H, Muckel E, et al (2002). Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by humanacetyltransferases and sulfotransferase. Carcinogenesis, 23, 1937-45. https://doi.org/10.1093/carcin/23.11.1937
  2. Arslan S, Silig Y, Pinarbasi H (2009). An investigation of the relationship between SULT1A1 Arg(213) his polymorphism and lung cancersusceptibility in a Turkish population. Cell Biochem Funct, 27, 211-5. https://doi.org/10.1002/cbf.1558
  3. Bardakci F, Arslan S, Bardakci S, et al (2008). Sulfotransferase 1A1 (SULT1A1) polymorphism and susceptibility to primary brain tumors. J Cancer Res Clin Oncol, 134, 109-14.
  4. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. https://doi.org/10.2307/3001666
  5. Chou HC, Lang NP, Kadlubar FF (1995). Metabolic activation of the N-hydroxy derivative of the carcinogen 4-aminobiphenyl by human tissue sulfotransferases. Carcinogenesis, 16, 413-7. https://doi.org/10.1093/carcin/16.2.413
  6. Coughtrie MW, Gilissen RA, Shek B, et al (1999). Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J, 337, 45-9. https://doi.org/10.1042/0264-6021:3370045
  7. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  8. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  9. Falany CN (1997). Enzymology of human cytosolic sulfotransferases. FASEB J, 11, 206-16. https://doi.org/10.1096/fasebj.11.4.9068609
  10. Greenlee RT, Murray T, Bolden S, et al (2000). Cancer statistics. CA Cancer J Clin, 50, 7-33. https://doi.org/10.3322/canjclin.50.1.7
  11. Hecht SS (1999). DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res, 424, 127-42. https://doi.org/10.1016/S0027-5107(99)00014-7
  12. Han DF, Zhou X, Hu MB, et al (2004). Sulfotransferase 1A1 (SULT1A1) polymorphism and breast cancer risk in Chinese women. Toxicol Lett, 150, 167-77. https://doi.org/10.1016/j.toxlet.2004.01.012
  13. Hirata H, Hinoda Y, Okayama N, et al (2008). CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer, 112, 1964-73. https://doi.org/10.1002/cncr.23392
  14. Jiang Y, Zhou L, Yan T, et al (2010). Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of caseresults control studies with subgroups of ethnic and menopausal statue. J Exp Clin Cancer Res, 29, 101. https://doi.org/10.1186/1756-9966-29-101
  15. Liang G, Miao X, Zhou Y, et al (2004). A functional polymorphism in the SULT1A1 gene (G638A) is associated with risk of lung cancer in relation to tobacco smoking. Carcinogenesis, 25, 773-8.
  16. MANTEL N, HAENSZEL W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  17. Nowell S, Ratnasinghe DL, Ambrosone CB, et al (2004). Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev, 13, 270-6. https://doi.org/10.1158/1055-9965.EPI-03-0047
  18. Ozawa S, Chou HC, Kadlubar FF, et al (1994). Activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b] pyridine by cDNA-expressed human and rat arylsulfotransferases. Jpn J Cancer Res, 85, 1220-8. https://doi.org/10.1111/j.1349-7006.1994.tb02933.x
  19. Ozawa S, Tang YM, Yamazoe Y, et al (1998). Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines. Chem Biol Interact, 109, 237-48. https://doi.org/10.1016/S0009-2797(97)00135-X
  20. Pachouri SS, Sobti RC, Kaur P, et al (2006). Impact of polymorphism in sulfotransferase gene on the risk of lung cancer. Cancer Genet Cytogenet, 171, 39-43. https://doi.org/10.1016/j.cancergencyto.2006.06.017
  21. Raftogianis RB, Wood TC, Otterness DM, et al (1997). Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleleswith TS PST phenotype. Biochem Biophys Res Commun, 239, 298-304. https://doi.org/10.1006/bbrc.1997.7466
  22. Raftogianis RB, Wood TC, Weinshilboum RM (1999). Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem Pharmacol, 58, 605-16. https://doi.org/10.1016/S0006-2952(99)00145-8
  23. Richard K, Hume R, Kaptein E, et al (2001). Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. J Clin Endocrinol Metab, 86, 2734-42. https://doi.org/10.1210/jc.86.6.2734
  24. Shopland DR, Eyre HJ, Pechacek TF (1991). Smokingattributable cancer mortality in 1991: is lung cancer now the leading cause of deathamong smokers in the United States? J Natl Cancer Inst, 83, 1142-8. https://doi.org/10.1093/jnci/83.16.1142
  25. Surh YJ, Tannenbaum SR (1995). Sulfotransferase-mediated activation of 7,8,9,10-tetrahydro-7-ol, 7,8-dihydrodiol, and 7,8,9,10-tetraol derivatives of benzo[a]pyrene. Chem Res Toxicol, 8, 693-8. https://doi.org/10.1021/tx00047a008
  26. Sun Y, Zang Z, Xu X, et al (2011). The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects. Breast Cancer Res Treat, 125, 215-9. https://doi.org/10.1007/s10549-010-0953-5
  27. Tamaki Y, Arai T, Sugimura H, et al (2011). Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab Pharmacokinet, 26, 516-22. https://doi.org/10.2133/dmpk.DMPK-11-RG-046
  28. Watabe T, Ishizuka T, Isobe M, et al (1982). A 7-hydroxymethyl sulfate ester as an active metabolite of 7,12-dimethylbenz[alpha]anthracene. Science, 215, 403-5. https://doi.org/10.1126/science.6800033
  29. Wang Y, Spitz MR, Tsou AM, et al (2002). Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer, 35, 137-42. https://doi.org/10.1016/S0169-5002(01)00406-8
  30. Wong CF, Liyou N, Leggett B, et al (2002). Association of the SULT1A1 R213H polymorphism with colorectal cancer. Clin Exp Pharmacol Physiol, 29, 754-8. https://doi.org/10.1046/j.1440-1681.2002.03738.x
  31. Wang LQ, James MO (2005). Sulfotransferase 2A1 forms estradiol-17-sulfate and celecoxib switches the dominant product fromestradiol-3-sulfate to estradiol-17-sulfate. J Steroid Biochem Mol Biol, 96, 367-74. https://doi.org/10.1016/j.jsbmb.2005.05.002
  32. Wang Z, Fu Y, Tang C, et al (2010). SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls. Breast Cancer Res Treat, 122, 193-8. https://doi.org/10.1007/s10549-009-0648-y

Cited by

  1. Methylenetetrahydrofolate Reductase Gene C677T Polymorphism and Lung Cancer: an Updated Meta-analysis vol.13, pp.5, 2012, https://doi.org/10.7314/APJCP.2012.13.5.2025
  2. Cytochrome and sulfotransferase gene variation in north African populations vol.17, pp.13, 2016, https://doi.org/10.2217/pgs-2016-0016
  3. Pharmacogenetics of SULT1A1 vol.15, pp.14, 2014, https://doi.org/10.2217/pgs.14.134